A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Description

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Conditions

Relapsed and/or Refractory Multiple Myeloma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Condition
Relapsed and/or Refractory Multiple Myeloma
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294

Duarte

City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010

San Francisco

UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco, California, United States, 94143

Stanford

Stanford University Medical Center, Stanford, California, United States, 94305

Denver

Colorado Blood Cancer Institute, Denver, Colorado, United States, 80218

New Haven

Yale Cancer Center, New Haven, Connecticut, United States, 06520

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Boston

Local Institution - 0023, Boston, Massachusetts, United States, 02215

New York

Icahn School of Medicine at Mount Sinai, New York, New York, United States, 10029

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease.
  • * Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.
  • * Participants in Part A and Part B Cohort 1 must have received at least 3 prior anti-myeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent.
  • * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • * Participants must have adequate organ function.
  • * Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.
  • * Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis.
  • * Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2027-11-29